Company Analysis

Zentalis Pharmaceuticals, Inc. (ZNTL)

Nasdaq: ZNTL · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2017
Grade3.9
◀ Past 3.5● Present 4.6▶ Future 3.5
5 est.

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Report filedMar 26, 2026Mar 26, 2025Feb 27, 2024Mar 1, 2023Feb 24, 2022Mar 25, 2021·
Revenue067,42500···
Research and development107,295167,768189,590172,734175,60184,90138,386
General and administrative37,71787,11564,35154,55340,94133,8868,459
Total operating expenses152,808258,619299,509227,287216,542118,78746,845
Operating income-152,808-191,194-299,509-227,287-216,542-118,787-46,845
Share of profit of equity-method investments00-16,014-16,282-1,83100
Income before income taxes-136,618-165,690-292,906-237,582-166,390-118,104-46,363
Income tax expense442177-601-469-29744415
Net income including non-controlling interests-137,060-165,867-292,305-237,113-166,093-118,548-46,378
Net income to non-controlling interests0-28-114-307-7,368-707-715
Net income-137,060-165,839-292,191-236,806-158,725-117,841-45,663
Earnings per share, basic-1.91-2.33-4.47-4.48-3.72-4.19·
Earnings per share, diluted-1.91-2.33-4.47-4.48-3.72r-4.19r-8.16
Weighted average shares, basic71,86971,08065,40952,85742,68828,1135,597
Weighted average shares, diluted71,86971,08065,40952,85742,68828,1135,597
Weighted average shares, basic and diluted·····28,1135,597
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Share of profit of equity-method investments its share of companies it partly ownsus-gaap:IncomeLossFromEquityMethodInvestments
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersus-gaap:NetIncomeLossAttributableToNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton ZNTL · research, not advice